Niva Bupa Health Insurance’s shares fell 5.2% to ₹76.1 on Friday, the first dip since early March, after the company detailed its stance on the IRDAI draft.
The IRDAI consultation paper, released September 23, proposes a 20% first‑year commission cap and tighter controls on distribution costs, a move the insurer says will lower commission expenses and let it keep prices flat.
Management noted that retail health—75% of June‑quarter GWP—should benefit, as lower commissions will be offset by higher volumes through direct‑to‑consumer channels. They also highlighted a 34‑35% GWP share that the company aims to elevate to 25% within two years.
Industry peers such as Bajaj Allianz and LIC have welcomed the draft, yet analysts warn that broker margins could compress; this concern is echoed by 10 of the 11 analysts covering the stock. The insurer’s combined ratio target of 98‑99% by year‑end signals an aggressive path to profitability.
Looking ahead, Niva Bupa plans a formal guidance review after Q2, maintains a long‑term ROE target of 15‑18%, and projects a 25% GWP share in two years, with a 98‑99% combined ratio as a near‑term milestone.
Motilal Oswal keeps a buy recommendation with a ₹100 target, an upside of 31%, and the majority of analysts remain bullish despite the recent dip, while the stock’s year‑to‑date gain sits at 1.4%.